Immune Score Based Radiomics in Nasopharyngeal Carcinoma

Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05126160

Enrollment

494

Registered

2021-11-18

Start date

2021-11-05

Completion date

2027-12-31

Last updated

2021-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Brief summary

In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.

Interventions

DIAGNOSTIC_TESTImmune Score Based Radiomics

To establish an immune score based radiomic staging system for nasopharyngeal carcinoma

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma. ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC \>4\*109/L, HGB\>90G/L, and PLT\>100\*109/L. Written informed consent

Exclusion criteria

Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.

Design outcomes

Primary

Measure	Time frame	Description
Area Under Curve (AUC)	Median follow-up time of 5 years for the whole group	The AUC of the immune score based radiomic staging system

Countries

China

Contacts

Primary ContactXiaozhong Chen

cxzfyun@sina.com0571-88128202

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026